Brisbane, Australia (ABN Newswire) - Australian medical device company, Oventus Medical Ltd. (ASX:OVN) is pleased to share Dr Chris Hart's interview on Financial News Network.

In the interview, Dr Hart discusses Oventus' three products cleared with the US FDA and the agreement with Modern Dental Group, the largest manufacturer and distributor of dental prosthetics in the world.

To view the interview, please click the link below:
http://www.abnnewswire.net/press/en/89683/ovn



About Oventus Medical Ltd:

Oventus Medical Ltd (ASX:OVN) is a Brisbane based medical device company that is commercialising a suite of oral appliances for the treatment of sleep apnoea and snoring. Unlike other oral appliances, the Oventus devices have a unique and patented airway within the device that delivers air to the back of the mouth bypassing multiple obstructions from the nose, soft palate and tongue. They are particularly designed for the many people that have nasal obstructions and consequently tend to mainly breathe through their mouth. While it may seem counterintuitive, the device actually prevents oral breathing. The O2Vent is designed to allow nasal breathing when the nose is unobstructed, but when obstruction is present, breathing is supplemented via the airways in the appliance.

A clinical study completed earlier this year showed the company's first generation product the O2Vent Mono(TM) is successful in treating OSA and that snoring was either eliminated or significantly reduced to 100 per cent of patients. The positive results included those people who had nasal obstructions and mainly breathed through their mouths, including when they were asleep. It also improves oxygen levels for patients.

According to a report published by the Sleep Health Foundation Australia, an estimated 1.5 million Australians suffer with sleep disorders and more than half of these suffer with obstructive sleep apnoea.

Continuous positive airway pressure (CPAP) is the most definitive medical therapy for obstructive sleep apnoea, OSA, however many patients have difficulty tolerating CPAP2. Oral appliances have emerged as an alternative to CPAP for obstructive sleep apnoea treatment.



Source:

Oventus Medical Ltd



Contact:

Mr Neil Anderson
Managing Director and CEO
M: 0403 003 475
 
Kyahn Williamson
WE Buchan
P: 03 9866 4722 or kwilliamson@buchanwe.com.au